Clinical Trial Update: Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sunitinib for patients with recurrent or metastatic head and neck squamous cell carcinoma, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Lip Squamous Cell Carcinoma
• Nasopharyngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Paranasal Sinus and Nasal Cavity Squamous Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Status: COMPLETED | Results posted: 2014-01-22